Form 4: Director Steve Elms Sells ADMA Biologics Shares

Steve Elms, a director at ADMA Biologics, sold a significant number of shares in two transactions on March 18 and 19, 2024.

Summary

• Steve Elms, a director of ADMA Biologics, sold shares of common stock on March 18 and 19, 2024.
• On March 18, 2024, he sold 49,887 shares at a weighted average price of $6.01, with prices ranging from $6.00 to $6.02.
• On March 19, 2024, he sold 411,829 shares at a weighted average price of $6.08, with prices ranging from $6.00 to $6.17.
• Following these transactions, Mr. Elms directly owns 76,441 shares, which includes 24,040 restricted stock units (RSUs) that will vest in two equal installments on the sixand 12-month anniversaries of the grant date, and 52,401 shares of common stock.
• He also indirectly owns 2,115,671 shares through Aisling Capital II LP.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the director's stock sale, which could raise concerns among investors, although the document itself is simply reporting the facts of the transaction.

Negatives

• A director selling a significant number of shares could be perceived negatively by investors.

Risks

• The market may interpret the director's sale as a lack of confidence in the company's future prospects.
• Significant stock sales by insiders can sometimes lead to increased market volatility.

Industry Context

Insider trading activity is always closely watched in the biotech industry, as it can provide signals about a company's prospects. However, it's important to consider the context of the trades, such as the individual's overall holdings and any potential diversification strategies.

Comparison to Industry Standards

• It's common for directors to periodically sell shares for personal financial planning reasons.
• The size of the sale should be compared to Mr. Elms' total holdings and to typical insider trading activity at comparable biotech companies to determine its significance.
• Companies like Grifols and CSL Behring, which are major players in the plasma-derived therapies market, also see insider trading activity, but the impact on their stock price varies depending on the size and context of the transactions.

Stakeholder Impact

• Shareholders may react to the news of the stock sale, potentially impacting the stock price.
• Employees may be concerned about the implications of the sale for the company's stability.

Key Dates